Eufillin-Solopharm Politvist, 2.4% 10 ml 10 pcs

Cough, Bronchospasm, Shortness of breath, Bronchial asthma, Bronchitis, Nocturnal apnea

Bronchoobstructive syndrome in bronchial asthma, bronchitis, pulmonary emphysema, cardiac asthma (mainly for relief of attacks); hypertension in the small circle of the circulation.

Cerebral vascular crises of atherosclerotic origin and as part of combined therapy for ischemic strokes and chronic insufficiency of the cerebral circulation to reduce intracranial pressure and cerebral edema.

Active ingredient

Aminophylline

Composition

Active substance:

aminophylline (eufylline for injection) (in terms of dry substance) – 240 mg

Auxiliary substances:

water for injection – up to 1ml.

.

How to take, the dosage

Eufillin is administered intramuscularly, deep into the upper quadrant of the gluteal muscle, 1 ml (240 mg) of solution.

Parenterally, eufillin is given up to 3 times a day, for up to 14 days.

The concentration of eufillin in blood serum should not exceed 20 µg/ml.

The highest doses of eufillin for adults intramuscularly: single dose – 0.5 g, daily – 1.5 g. Higher doses for children intramuscularly: single dose – 7 mg/kg, daily – 15 mg/kg.

Correcting the dosage regimen may be required in patients with heart failure, liver dysfunction, chronic alcoholism. In elderly patients the dose lowering (single dose – 0.3 g) may be required. It is recommended to increase the dose for smokers because of accelerated elimination of the drug from the body (single dose – 0.7 g).

Interaction

Ephedrine, beta-adrenergic stimulants, caffeine and furosemide enhance the effect of the drug. In combination with phenobarbital, diphenin, rifampicin, isoniazid, carbamazepine or sulfinpyrazone a decrease in the effectiveness of eufillin is observed, which may require increasing the used doses of the drug.

The clearance of the drug decreases when prescribed in combination with macrolide antibiotics, lincomycin, allopurinol, cimetidine, isoprenaline, beta-adrenoblockers, which may require reduction of the dose.

The oral estrogen-containing contraceptives, anti-diarrheal drugs, intestinal sorbents weaken and H2-histaminoblockers, slow calcium channel blockers, mexiletine enhance action (they bind to cytochrome P450 enzymatic system and slow down eufillin metabolism). If used in combination with epoxacin and other fluoroquinolines, the dose of eufillin is reduced. The drug suppresses therapeutic effects of lithium carbonate and beta-adrenoblockers.

The administration of beta-adrenoblockers interferes with the bronchodilator effect of eufillin and may cause bronchospasm. Eufillin potentiates the effect of diuretics by increasing glomerular filtration and reducing tubular reabsorption. With caution, eufylline is prescribed concomitantly with anticoagulants, with other theophylline or purine derivatives.

It is not recommended to use eufylline with agents that excite the central nervous system (increases neurotoxicity). Eufillin solution for intramuscular administration should not be diluted or mixed with other solutions.

Special Instructions

Euphylline solutions are not administered under the skin because they have a local irritant effect.

Impact on the ability to operate vehicles and machinery:When treated with the drug, patients are not recommended for 24 hours to perform fast-acting and risky work, such as driving vehicles.

.

Contraindications

Severe arterial hypotension or hypertension, paroxysmal tachycardia, extrasystole, myocardial infarction with cardiac rhythm disturbances, epilepsy, increased seizure readiness, hypertrophic obstructive cardiomyopathy, thyrotoxicosis, pulmonary edema, severe coronary insufficiency, hepatic and/or renal insufficiency, hemorrhagic stroke, retinal hemorrhage, bleeding in recent history, hypersensitivity to the drug.

With caution:

Pregnancy, newborn period, age over 55 years and uncontrolled hypothyroidism (possibility of cumulation), sepsis, prolonged hyperthermia, gastroesophageal reflux, prostate adenoma.

The drug is administered with caution in patients with significant liver and kidney function abnormalities, gastric and duodenal ulcer.

.

Side effects

Digestive system disorders: gastroesophageal reflux, gastralgia, nausea, vomiting, heartburn, aggravation of ulcer disease.

Nervous system disorders: headache, insomnia, agitation, anxiety, restlessness, irritability, dizziness, tremor.

Cardiovascular system disorders: palpitations, arrhythmias, tachycardia, abnormal heart rhythm, decreased blood pressure, cardialgia, increased frequency of angina attacks.

Allergic reactions: skin rash, skin itching, fever.

Local reactions: reactions at the injection site – hyperemia, pain.

Others: chest pain, tachypnoea, albuminuria, hematuria, hypoglycemia, increased sweating, increased diuresis.

.

Overdose

In overdose anorexia, diarrhea, nausea, vomiting, epigastric pain, gastrointestinal bleeding, tachycardia, ventricular arrhythmias, tremor, generalized convulsions, hyperventilation, sharp decrease of blood pressure are observed.

The treatment of overdose depends on the clinical picture and includes discontinuation of the drug, stimulation of its elimination from the body (forced diuresis, hemosorption, plasma sorption, hemodialysis, peritoneal dialysis) and application of symptomatic measures.

Diazepam (in injections) is used to relieve seizures. Barbiturates should not be used.

Hemodialysis is recommended in severe intoxication (eufillin content over 50 g/l).